Tom Powles, Professor of urology cancer at the University of London and the Director of Barts Cancer Centre, shared a post on X:
“Belzutifan significantly outperformed everolimus in heavily pretreated clear cell renal cancer.
Respiratory Rate, Progression-free survival , Quality of life but no Oculus Sinister. Data suggests belzutifan is better in less heavily treated disease and in combination. 1st line and adjuvant trials awaited.”
Source: Tom Powles/X
